Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 208.19 Billion KRW | 61.29% |
| 2022 | 129.08 Billion KRW | 9.99% |
| 2021 | 117.35 Billion KRW | -9.57% |
| 2020 | 129.77 Billion KRW | 109.15% |
| 2019 | 62.04 Billion KRW | -22.61% |
| 2018 | 80.17 Billion KRW | 221.64% |
| 2017 | 24.92 Billion KRW | 8.38% |
| 2016 | 23 Billion KRW | -19.32% |
| 2015 | 28.5 Billion KRW | 6.3% |
| 2014 | 26.81 Billion KRW | -1.18% |
| 2013 | 27.13 Billion KRW | -47.49% |
| 2012 | 51.68 Billion KRW | -22.9% |
| 2011 | 67.04 Billion KRW | 34.25% |
| 2010 | 49.93 Billion KRW | -14.98% |
| 2009 | 58.73 Billion KRW | 3.88% |
| 2008 | 56.54 Billion KRW | 27.39% |
| 2007 | 44.38 Billion KRW | 75.46% |
| 2006 | 25.29 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 119.93 Billion KRW | -36.86% |
| 2024 Q1 | 189.93 Billion KRW | -2.47% |
| 2023 Q2 | 119.59 Billion KRW | 0.96% |
| 2023 FY | 208.19 Billion KRW | 61.29% |
| 2023 Q4 | 194.75 Billion KRW | 34.97% |
| 2023 Q1 | 118.46 Billion KRW | -8.22% |
| 2023 Q3 | 144.29 Billion KRW | 20.65% |
| 2022 Q3 | 127.71 Billion KRW | 10.68% |
| 2022 Q2 | 115.39 Billion KRW | -5.61% |
| 2022 Q1 | 122.25 Billion KRW | 4.17% |
| 2022 FY | 129.08 Billion KRW | 9.99% |
| 2022 Q4 | 129.08 Billion KRW | 1.07% |
| 2021 Q2 | 124.03 Billion KRW | -5.09% |
| 2021 FY | 117.35 Billion KRW | -9.57% |
| 2021 Q3 | 105.09 Billion KRW | -15.27% |
| 2021 Q4 | 117.35 Billion KRW | 11.67% |
| 2021 Q1 | 130.68 Billion KRW | 0.7% |
| 2020 FY | 129.77 Billion KRW | 109.15% |
| 2020 Q2 | 138.22 Billion KRW | 3.32% |
| 2020 Q3 | 118.28 Billion KRW | -14.43% |
| 2020 Q4 | 129.77 Billion KRW | 9.72% |
| 2020 Q1 | 133.78 Billion KRW | 115.61% |
| 2019 Q1 | 76.15 Billion KRW | -5.01% |
| 2019 Q4 | 62.04 Billion KRW | 8.77% |
| 2019 FY | 62.04 Billion KRW | -22.61% |
| 2019 Q2 | 76.95 Billion KRW | 1.04% |
| 2019 Q3 | 57.04 Billion KRW | -25.87% |
| 2018 Q1 | 28 Billion KRW | 12.33% |
| 2018 FY | 80.17 Billion KRW | 221.64% |
| 2018 Q4 | 80.17 Billion KRW | -12.06% |
| 2018 Q3 | 91.17 Billion KRW | 128.89% |
| 2018 Q2 | 39.83 Billion KRW | 42.25% |
| 2017 Q2 | 23.49 Billion KRW | -3.41% |
| 2017 Q1 | 24.32 Billion KRW | 5.75% |
| 2017 Q4 | 24.92 Billion KRW | 2.52% |
| 2017 FY | 24.92 Billion KRW | 8.38% |
| 2017 Q3 | 24.31 Billion KRW | 3.49% |
| 2016 Q4 | 23 Billion KRW | -8.93% |
| 2016 FY | 23 Billion KRW | -19.32% |
| 2016 Q1 | 51.71 Billion KRW | 81.43% |
| 2016 Q2 | 27.61 Billion KRW | -46.61% |
| 2016 Q3 | 25.25 Billion KRW | -8.53% |
| 2015 Q1 | 40.68 Billion KRW | 51.73% |
| 2015 FY | 28.5 Billion KRW | 6.3% |
| 2015 Q4 | 28.5 Billion KRW | 3.57% |
| 2015 Q3 | 27.52 Billion KRW | 5.39% |
| 2015 Q2 | 26.11 Billion KRW | -35.81% |
| 2014 Q4 | 26.81 Billion KRW | -0.32% |
| 2014 FY | 26.81 Billion KRW | -1.18% |
| 2014 Q2 | 28.34 Billion KRW | 0.0% |
| 2014 Q3 | 26.9 Billion KRW | -5.09% |
| 2013 Q4 | 27.13 Billion KRW | 0.0% |
| 2013 FY | 27.13 Billion KRW | -47.49% |
| 2013 Q1 | 65.53 Billion KRW | 26.78% |
| 2012 Q4 | 51.68 Billion KRW | -26.56% |
| 2012 Q1 | 73.75 Billion KRW | 0.0% |
| 2012 FY | 51.68 Billion KRW | -22.9% |
| 2012 Q2 | 72.58 Billion KRW | -1.59% |
| 2012 Q3 | 70.38 Billion KRW | -3.03% |
| 2011 FY | 67.04 Billion KRW | 34.25% |
| 2011 Q3 | 51.39 Billion KRW | -2.37% |
| 2011 Q1 | 49.93 Billion KRW | -15.44% |
| 2011 Q2 | 52.63 Billion KRW | 5.41% |
| 2010 Q3 | 61.19 Billion KRW | 3.02% |
| 2010 Q4 | 59.05 Billion KRW | -3.5% |
| 2010 Q2 | 59.4 Billion KRW | 1.13% |
| 2010 Q1 | 58.73 Billion KRW | -0.98% |
| 2010 FY | 49.93 Billion KRW | -14.98% |
| 2009 Q4 | 59.32 Billion KRW | -0.57% |
| 2009 Q3 | 59.66 Billion KRW | -0.85% |
| 2009 Q2 | 60.17 Billion KRW | 0.0% |
| 2009 FY | 58.73 Billion KRW | 3.88% |
| 2008 Q4 | 63.19 Billion KRW | 5.54% |
| 2008 Q2 | 41.2 Billion KRW | 0.0% |
| 2008 Q3 | 59.87 Billion KRW | 45.31% |
| 2008 FY | 56.54 Billion KRW | 27.39% |
| 2007 FY | 44.38 Billion KRW | 75.46% |
| 2007 Q2 | 29.58 Billion KRW | 0.0% |
| 2007 Q3 | 35.64 Billion KRW | 20.49% |
| 2007 Q4 | 40.02 Billion KRW | 12.29% |
| 2006 FY | 25.29 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -167.407% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 77.608% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 70.556% |
| HANDOK Inc. | 449.7 Billion KRW | 53.704% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -143.021% |
| Yuhan Corporation | 712.33 Billion KRW | 70.773% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 67.053% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -1209.871% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 75.559% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -288.946% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -1.128% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -176.965% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -40.87% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -195.729% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -167.407% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -471.402% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 17.103% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 5.667% |
| JW Holdings Corporation | 827.51 Billion KRW | 74.841% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 52.357% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 64.519% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 45.153% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -162.539% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -197.562% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 14.27% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 36.966% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -167.407% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 57.512% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 75.735% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 45.153% |
| Yuhan Corporation | 712.33 Billion KRW | 70.773% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 56.427% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -52.004% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 59.704% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 45.153% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -34.724% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -131.42% |
| CKD Bio Corp. | 170.76 Billion KRW | -21.923% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 14.58% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -32.057% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -383.964% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -162.539% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 67.084% |
| Boryung Corporation | 373.1 Billion KRW | 44.199% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -1.128% |
| JW Lifescience Corporation | 96.44 Billion KRW | -115.875% |